IBD Videos Get market updates, educational videos, webinars, and stock analysis. BREAKING: Futures Rise After Market Holiday BillionToOne (BLLN) has been trading for just 14 days since it went public on Nov. 6. But the IPO stock has formed a base that has a buy point of 123.84, according to IBD MarketSurge chart analysis tools. Shares broke out on Monday and are in a 5% buy zone that goes up to 130.03. The stock is also on… INVESTING RESOURCES Take a Trial Today Get instant access to exclusive stock lists, ...

Core Points - BillionToOne, Inc. successfully closed its upsized initial public offering (IPO) of 5,233,765 shares of Class A common stock at a public offering price of $60.00 per share, resulting in gross proceeds of approximately $314.0 million before deductions [1] - The IPO included the full exercise of the underwriters' option to purchase an additional 682,665 shares [1] - The company's Class A common stock began trading on the Nasdaq Global Select Market under the ticker symbol "BLLN" on November 6, 2025 [1] Company Overview - BillionToOne is a molecular diagnostics company headquartered in Menlo Park, California, focused on creating powerful and accurate tests that are accessible to all [4] - The company utilizes a patented technology called Quantitative Counting Templates™ (QCT™), which is the only multiplex technology capable of accurately counting DNA molecules at the single-molecule level [4] Offering Details - The registration statement related to the securities was filed with the U.S. Securities and Exchange Commission and became effective on November 5, 2025 [2] - A prospectus describing the terms of the offering has been filed with the SEC and is available on their website [2]

Core Viewpoint - Shares of BillionToOne (BLLN) have doubled on their opening day of trading, indicating strong investor optimism regarding the company's innovative technology for disease detection from a single drop of blood [1] Group 1: Company Overview - BillionToOne has developed a revolutionary technology aimed at detecting diseases, which has garnered significant attention from investors [1] Group 2: Market Reaction - The stock price of BillionToOne experienced a doubling on its first trading day, reflecting a positive market sentiment and high expectations for the company's future prospects [1]

Core Insights - Three companies, Evommune, BillionToOne, and Grupo Aeroméxico, went public on November 6, raising a total of $646 million, averaging approximately $215 million per company [1] Group 1: Evommune (EVMN) - Evommune opened at $17.25, a 7.25% increase from the offering price, and closed at $20.23, marking a 26.44% rise with a total market capitalization of $608 million [2][5] - The company issued 9.38 million shares at an offering price of $16, raising $150 million [5] - Evommune focuses on innovative therapies for immune-mediated inflammatory mechanisms, projecting $3 million in revenue and a net loss of $28.12 million for the first half of 2025 [5] Group 2: BillionToOne (BLLN) - BillionToOne opened at $100, a 66.67% increase from the offering price, and closed at $108.94, reflecting an 81.57% gain with a total market capitalization of $4.795 billion [6][9] - The company issued 4.55 million shares at an offering price of $60, raising $273 million [9] - BillionToOne specializes in molecular diagnostics, developing prenatal and oncology diagnostic products through its single-molecule next-generation sequencing (smNGS) platform, with projected revenue of $126 million and a net loss of $4.23 million for the first half of 2025 [9] Group 3: Grupo Aeroméxico (AERO) - Grupo Aeroméxico opened at $19.16, a slight increase of 0.84%, and closed at $20.35, resulting in a 7.11% rise with a total market capitalization of $2.969 billion [9][11] - The company issued 11.73 million shares at an offering price of $19, raising $223 million [11] - Grupo Aeroméxico provides domestic and international flight services, covering 22 countries and 52 international cities, with projected revenue of $2.498 billion and a net profit of $89.97 million for the first half of 2025 [11]

Group 1 - BillionToOne officially listed on NASDAQ with an opening stock price surge of 81.57%, reaching a market capitalization of nearly $4.8 billion [1] - The IPO price was set at $60, with the stock opening at $100 and peaking at $123.45 during trading, indicating strong investor interest [1] - The company raised $273 million by issuing 4.55 million shares, with the offering size increased by 20% within regulatory limits [1] Group 2 - BillionToOne specializes in non-invasive prenatal testing (NIPT) and tumor blood testing based on single-molecule sequencing technology [2] - The company reported an 82% year-over-year revenue growth and a doubling of gross profit for the first half of the year, showcasing strong commercialization capabilities [2] - The successful IPO of BillionToOne is seen as a significant signal of recovery in the IPO market, particularly for high-growth medical technology companies [2]

Core Insights - BillionToOne, Inc. successfully completed an upsized initial public offering (IPO) of 4.6 million shares at $60 per share, raising approximately $273.1 million in gross proceeds [1] - The shares began trading on the Nasdaq Global Select Market on November 6, 2025, with the offering expected to close on November 7, 2025 [1] Company Representation - Gunderson Dettmer has represented BillionToOne through various financing rounds, including Series A and late-stage equity and debt private rounds, providing strategic counsel from early funding to public market entry [2] Underwriters - J.P. Morgan, Piper Sandler, Jefferies, and William Blair are acting as joint book-running managers for the IPO, with Stifel, Wells Fargo Securities, and BTIG also participating as book-running managers [3] Legal Team - The Gunderson deal team included several partners and associates specializing in corporate law and public offerings, showcasing the firm's expertise in navigating complex capital markets [4]

CONCLUDED Stock Market News From Nov. 6, 2025: Dow Falls After New Labor Market Data Last Updated: 2 hours ago What Shutdown? The IPO Window Is Still Open for Some Companies By Paul R. La Monica The government shutdown has slowed down the IPO market. But the fact that the Securities and Exchange Commission's operations have been curtailed while Washington is essentially in dark mode hasn't halted stock market debuts entirely. Some companies that had already filed paperwork before the shutdown have been able ...

BillionToOne has become a newly minted public company, raising $273.1m in an upsized initial public offering (IPO), despite the longest government shutdown in US history hampering those wishing to join the stock exchange. The US-based company sold around 4.5 million shares of its common stock at $60 each. The molecular test developer initially offered around 3.8 million shares that were expected to fall between $49 and $55 each. BillionToOne’s IPO has given it a market valuation at around $2.6bn. The mol ...

Core Insights - Shares of BillionToOne increased by 66.67% during their Nasdaq debut, indicating strong market interest and investor confidence in the company [1] - The market valuation of BillionToOne reached $4.4 billion following the initial public offering, reflecting the company's growth potential in the molecular diagnostics sector [1] Company Summary - BillionToOne is a molecular diagnostics firm that has successfully launched its shares on Nasdaq, marking a significant milestone for the company [1] - The substantial rise in share price on debut suggests a positive reception from investors, which may enhance the company's visibility and credibility in the industry [1] Industry Context - The molecular diagnostics industry is experiencing increased investor interest, as evidenced by BillionToOne's successful IPO and significant valuation [1] - The performance of BillionToOne may indicate broader trends in the diagnostics market, where innovative companies are attracting capital and attention [1]

Core Insights - Molecular diagnostics firm BillionToOne successfully raised $273.1 million in its U.S. initial public offering (IPO) [1] - The company priced its shares above the marketed range, indicating strong investor demand [1] Company Summary - BillionToOne specializes in molecular diagnostics, a sector focused on the analysis of biological markers in the genome and proteome [1] - The successful IPO reflects the growing interest and investment in the molecular diagnostics industry [1] Financial Highlights - The total amount raised in the IPO was $273.1 million, showcasing significant capital influx for the company [1] - Pricing of shares above the marketed range suggests a positive market reception and confidence in the company's future prospects [1]